SEC Form 4 · accession 0001106578-26-000120
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairperson & CEO · Director
Period of report
Aug 13, 2026
Accepted (ET)
Aug 14, 2026 · 4:41 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 13, 2026 | M | 9,500 | $135.42 | A | 333,943 | I | by Trust |
| Common StockF3,F2 | Aug 13, 2026 | S | 1,253 | $500.0779 | D | 332,690 | I | by Trust |
| Common StockF4,F2 | Aug 13, 2026 | S | 1,328 | $500.932 | D | 331,362 | I | by Trust |
| Common StockF5,F2 | Aug 13, 2026 | S | 1,519 | $501.8777 | D | 329,843 | I | by Trust |
| Common StockF6,F2 | Aug 13, 2026 | S | 440 | $502.9277 | D | 329,403 | I | by Trust |
| Common StockF7,F2 | Aug 13, 2026 | S | 160 | $503.8259 | D | 329,243 | I | by Trust |
| Common StockF8,F2 | Aug 13, 2026 | S | 961 | $505.1792 | D | 328,282 | I | by Trust |
| Common StockF9,F2 | Aug 13, 2026 | S | 1,679 | $506.1612 | D | 326,603 | I | by Trust |
| Common StockF10,F2 | Aug 13, 2026 | S | 920 | $507.1417 | D | 325,683 | I | by Trust |
| Common StockF11,F2 | Aug 13, 2026 | S | 640 | $508.7591 | D | 325,043 | I | by Trust |
| Common StockF12,F2 | Aug 13, 2026 | S | 200 | $509.9242 | D | 324,843 | I | by Trust |
| Common StockF13,F2 | Aug 13, 2026 | S | 160 | $511.121 | D | 324,683 | I | by Trust |
| Common StockF14,F2 | Aug 13, 2026 | S | 240 | $512.3595 | D | 324,443 | I | by Trust |
| Common Stock | holding | — | — | — | 40,513 | D | ||
| Common Stock | holding | — | — | — | 166 | I | by Spouse | |
| Common StockF15 | holding | — | — | — | 249,108 | I | by Trust | |
| Common StockF16 | holding | — | — | — | 45,596 | I | by Trust | |
| Common StockF17 | holding | — | — | — | 8,902 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF18 | $135.42 | Aug 13, 2026 | M | 9,500 | D | Mar 15, 2023 | Mar 15, 2027 | Common Stock | 9,500 | 141,910 | I |
Explanation of responses
- F1This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10This transaction was executed in multiple trades at prices ranging from $506.74 to $507.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11This transaction was executed in multiple trades at prices ranging from $508.09 to $509.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12This transaction was executed in multiple trades at prices ranging from $509.51 to $510.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13This transaction was executed in multiple trades at prices ranging from $510.54 to $511.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14This transaction was executed in multiple trades at prices ranging from $511.83 to $512.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F15Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F16Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F17Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F18Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3This transaction was executed in multiple trades at prices ranging from $499.46 to $500.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $500.46 to $501.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $501.47 to $502.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $502.63 to $503.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $503.67 to $504.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8This transaction was executed in multiple trades at prices ranging from $504.73 to $505.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9This transaction was executed in multiple trades at prices ranging from $505.73 to $506.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.